Synonym
Pancopride; Pancopridum; LAS 30451; LAS-30451; LAS30451;
IUPAC/Chemical Name
4-amino-5-chloro-2-(cyclopropylmethoxy)-N-(quinuclidin-3-yl)benzamide
InChi Key
DBQMQBCSKXTCIJ-UHFFFAOYSA-N
InChi Code
InChI=1S/C18H24ClN3O2/c19-14-7-13(17(8-15(14)20)24-10-11-1-2-11)18(23)21-16-9-22-5-3-12(16)4-6-22/h7-8,11-12,16H,1-6,9-10,20H2,(H,21,23)
SMILES Code
O=C(NC1CN2CCC1CC2)C3=CC(Cl)=C(N)C=C3OCC4CC4
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
Preparing Stock Solutions
The following data is based on the
product
molecular weight
349.85
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Dewland P, Pérez Campos A, Martinez-Tobed A. Single dose pharmacokinetics and tolerance of pancopride in healthy volunteers. Arzneimittelforschung. 1995 Feb;45(2):177-83. PubMed PMID: 7710444.
2: Grande L, Lacima G, Pérez A, Zayas JM. Lack of effect of a 5-HT3 antagonist, pancopride, on lower oesophageal sphincter pressure in volunteers. Br J Clin Pharmacol. 1995 Oct;40(4):401-3. PubMed PMID: 8554943; PubMed Central PMCID: PMC1365160.
3: Fernández AG, Puig J, Beleta J, Doménech T, Bou J, Berga P, Gristwood RW, Roberts DJ. Pancopride, a potent and long-acting 5-HT3 receptor antagonist, is orally effective against anticancer drug-evoked emesis. Eur J Pharmacol. 1992 Nov 10;222(2-3):257-64. PubMed PMID: 1451737.
4: Salva P, Costa J, Pérez-Campos A, Martínez-Tobed A. Repeated dose pharmacokinetics of pancopride in human volunteers. Biopharm Drug Dispos. 1994 Nov;15(8):643-51. PubMed PMID: 7888596.
5: Aranda E, Barneto IC, Rubio MJ, Gonzalez R, Garcia A, Perez A. Prevention of highly emetogenic chemotherapy-induced vomiting: a double blind, randomized crossover study to compare pancopride (LAS 30451) and pancopride plus dexamethasone. Tumori. 1995 Nov-Dec;81(6):432-4. PubMed PMID: 8804470.
6: Pérez Campos A. [The clinical development of an antiemetic in oncology. A meta-analysis]. Med Clin (Barc). 1994 Sep 17;103(8):281-6. Spanish. PubMed PMID: 7967877.
7: Martin M, Rosell R, Guillem V, Díaz-Rubio E, Moreno I, Soriano V, Fernández A, Pérez A. LAS 30451: a novel 5-HT3 antagonist. Eur J Cancer. 1993;29A Suppl 1:S33-4. PubMed PMID: 8427723.
